Article Sidebar
Published:
Jun 4, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of cognitive rehabilitation training combined with butylphthalide soft capsules and ginkgo-leaf tablets on patients with mild Alzheimer's disease
Abstract
Purpose: To study the impact of a combination of cognitive rehabilitation training, butylphthalide soft capsules and ginkgo-leaf tablets on patients with mild Alzheimer’s disease (AD).
Methods: One hundred and twenty-eight (128) mild AD patients were randomly assigned to medication treatment group (MT group, n = 64) and joint training group (JT group, n = 64). Both groups were treated with butylphthalide soft capsules and ginkgo-leaf tablets, while the JT group additionally received cognitive rehabilitation training. Therapeutic effects and adverse drug reactionsin the two groups were assessed.
Results: Total effectiveness was significantly higher in JT patients (84.38 %) than in MT patients (60.94 %; χ2 = 8.9320). After treatment, Mini-Mental State Exam (MMSE), Activity of Daily Living (ADL) and ADAS-cog scores in the JT group were significantly better than those in the MT group, (p < 0.05). There were significantly lower plasma NO, serum VEGF and MDA levels in JT patients than in MT patients. CRP and Hcy levels were markedly lower in JT than in MT patients. The incidence of adverse reactions in both groups was comparable (p > 0.05).
Conclusion: Rehabilitation training in combination with butylphthalide soft capsule and ginkgo-leaf tablets produce significant therapeutic impact on mild AD patients. The combination therapy delays cognitive decline and memory loss in AD patients, improves their serological indicators, and lowers the incidence of adverse reactions.
